190 related articles for article (PubMed ID: 33551434)
1. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
3. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.
Kanokwongnuwat W; Larbcharoensub N; Sriphrapradang C; Suppasilp C; Thamnirat K; Sakulpisuti C; Kositwattanarerk A; Utamakul C; Sritara C; Chamroonrat W
Endocrine; 2022 Jun; 77(1):134-142. PubMed ID: 35476179
[TBL] [Abstract][Full Text] [Related]
4. Identification of patients with Graves' disease who benefit from high-dose radioactive iodine therapy.
Watanabe S; Okamoto S; Akikawa K; Miyamoto N; Okamura-Kawasaki M; Uchiyama Y; Takenaka J; Toyonaga T; Hirata K; Kudo K
Ann Nucl Med; 2022 Nov; 36(11):923-930. PubMed ID: 35972673
[TBL] [Abstract][Full Text] [Related]
5. Radioactive Iodine Therapy of Graves' Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation.
Mihailescu DV; Hoscheit C; Fogelfeld L
Endocr Pract; 2024 Apr; 30(4):333-339. PubMed ID: 38307459
[TBL] [Abstract][Full Text] [Related]
6. Papillary thyroid microcarcinoma: an over-treated malignancy?
Wang TS; Goffredo P; Sosa JA; Roman SA
World J Surg; 2014 Sep; 38(9):2297-303. PubMed ID: 24791670
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine treatment in pediatric Graves' disease and thyroid carcinoma.
Yuan L; Yang J
J Pediatr Endocrinol Metab; 2011; 24(11-12):877-83. PubMed ID: 22308835
[TBL] [Abstract][Full Text] [Related]
8. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.
Hu G; Zhu W; Yang W; Wang H; Shen L; Zhang H
World J Surg; 2016 Jan; 40(1):100-9. PubMed ID: 26578322
[TBL] [Abstract][Full Text] [Related]
10. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
11. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
12. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
13. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
Shen G; Kou Y; Liu B; Huang R; Kuang A
Nucl Med Commun; 2019 Jan; 40(1):8-13. PubMed ID: 30312216
[TBL] [Abstract][Full Text] [Related]
14. Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves' disease.
Kanokwongnuwat W; Penpong N
BMC Endocr Disord; 2024 Apr; 24(1):54. PubMed ID: 38664774
[TBL] [Abstract][Full Text] [Related]
15. Radioactive Iodine Ablation Decrease Recurrences in Papillary Thyroid Microcarcinoma with Lateral Lymph Node Metastasis in Chinese Patients.
Xue S; Wang P; Liu J; Chen G
World J Surg; 2017 Dec; 41(12):3139-3146. PubMed ID: 28741199
[TBL] [Abstract][Full Text] [Related]
16. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
17. Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.
Zhao M; Shi X; Zhang J; Deng S; Zhou Y; Wen R; Lu Y; Zhang B
Comput Math Methods Med; 2022; 2022():8028846. PubMed ID: 36110571
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Radioactive Iodine Therapy in Childhood Graves’ Disease in Khon Kaen, Thailand.
Getsuwan S; Wiromrat P; Panamonta O; Panamonta M; Paireepinas S
J Med Assoc Thai; 2016 Aug; 99 Suppl 5():S112-9. PubMed ID: 29905996
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
